Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells

Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells

IntroductionAlthough the engineering of T cells to co-express immunostimulatory cytokines has been shown to enhance the therapeutic efficacy of adoptive T cell therapy, the uncontrolled systemic release of potent cytokines can lead to severe adverse effects. To address this, we site-specifically ins...

Full description

Bibliographic Details
Main Authors: Segi Kim, Cho I Park, Sunhwa Lee, Hyeong Ryeol Choi, Chan Hyuk Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
TCR-T
interleukin-12
CRISPR/Cas9
NY-ESO-1
PD-1
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1062365/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1062365/full

Similar Items